Covered recipient · General Payments record
PEDRO M BARATA
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$194,477.35
162 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $97,370.00 | 18 |
| Travel and Lodging | $57,536.83 | 55 |
| Consulting Fee | $32,254.00 | 11 |
| Food and Beverage | $5,318.43 | 76 |
| Honoraria | $1,980.00 | 1 |
| Education | $18.09 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $74,422.73 | 34 |
| Astellas Pharma US Inc | $36,433.86 | 29 |
| Merck Sharp & Dohme LLC | $33,211.03 | 24 |
| Bayer Healthcare Pharmaceuticals Inc. | $15,048.22 | 20 |
| Exelixis Inc. | $11,740.05 | 12 |
| AstraZeneca Pharmaceuticals LP | $6,920.89 | 15 |
| Janssen Biotech, Inc. | $5,593.97 | 4 |
| Astellas Pharma Europe Ltd | $3,570.00 | 2 |
| Telix Pharmaceuticals | $2,827.00 | 11 |
| Janssen Scientific Affairs, LLC | $2,677.90 | 3 |
| E.R. Squibb & Sons, L.L.C. | $1,805.95 | 2 |
| Sumitomo Pharma America, Inc. | $124.39 | 2 |
| Astellas Pharma Global Development | $32.66 | 1 |
| Gilead Sciences, Inc. | $28.49 | 1 |
| Novartis Pharmaceuticals Corporation | $24.73 | 1 |
| Aveo Pharmaceuticals, Inc. | $15.48 | 1 |
Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
PEDRO M BARATA
NPI 1841746542 · CMS profile ID 5698885
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
NEW ORLEANS, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1841746542?year=2024&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- PEDRO M BARATA, NPI 1841746542, CMS profile ID 5698885. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841746542?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). PEDRO M BARATA, NPI 1841746542, CMS profile ID 5698885. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841746542?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- PEDRO M BARATA, NPI 1841746542, CMS profile ID 5698885, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1841746542?year=2024&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
162 matching records · $194,477.35 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 162.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | $325.00 | 06/29/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141722658 | CMS |
| Merck Sharp & Dohme LLC | $616.09 | 06/29/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141878745 | CMS |
| Merck Sharp & Dohme LLC | $4,270.00 | 06/26/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141722812 | CMS |
| Merck Sharp & Dohme LLC | $75.00 | 06/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141878603 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,779.00 | 06/20/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101211796 | CMS |
| PFIZER INC. | $104.79 | 06/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131586164 | CMS |
| PFIZER INC. | $618.00 | 06/17/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131595175 | CMS |
| PFIZER INC. | $550.79 | 06/17/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131596036 | CMS |
| PFIZER INC. | $1,752.06 | 06/17/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131596041 | CMS |
| Merck Sharp & Dohme LLC | $4.31 | 06/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141705142 | CMS |
| Merck Sharp & Dohme LLC | $32.55 | 06/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141705144 | CMS |
| Merck Sharp & Dohme LLC | $32.55 | 06/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141705146 | CMS |
| Merck Sharp & Dohme LLC | $8.68 | 06/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141707922 | CMS |
| Merck Sharp & Dohme LLC | $4,839.16 | 06/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141705140 | CMS |
| Merck Sharp & Dohme LLC | $18.93 | 06/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141707756 | CMS |
| Merck Sharp & Dohme LLC | $2.17 | 06/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141707912 | CMS |
| Merck Sharp & Dohme LLC | $308.13 | 06/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141707916 | CMS |
| Merck Sharp & Dohme LLC | $8.54 | 06/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141707918 | CMS |
| Merck Sharp & Dohme LLC | $32.55 | 06/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141707920 | CMS |
| PFIZER INC. | $8,100.00 | 06/04/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131602280 | CMS |
| PFIZER INC. | $135.00 | 06/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131329327 | CMS |
| AstraZeneca Pharmaceuticals LP | $106.06 | 06/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104671653 | CMS |
| AstraZeneca Pharmaceuticals LP | $27.22 | 06/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105491483 | CMS |
| Telix Pharmaceuticals | $167.07 | 06/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1081981714 | CMS |
| Exelixis Inc. | $174.00 | 06/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1138563708 | CMS |
| Janssen Scientific Affairs, LLC | $35.76 | 06/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078851322 | CMS |
| Sumitomo Pharma America, Inc. | $37.29 | 05/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1148824504 | CMS |
| Gilead Sciences, Inc. | $28.49 | 05/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133799332 | CMS |
| Merck Sharp & Dohme LLC | $114.23 | 05/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141876426 | CMS |
| Astellas Pharma US Inc | $14.66 | 05/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139359323 | CMS |
| Merck Sharp & Dohme LLC | $4,270.00 | 05/16/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141722808 | CMS |
| PFIZER INC. | $1,440.00 | 05/15/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131915502 | CMS |
| AstraZeneca Pharmaceuticals LP | $123.36 | 05/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104613564 | CMS |
| PFIZER INC. | $229.50 | 05/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131966551 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.61 | 05/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104662215 | CMS |
| Merck Sharp & Dohme LLC | $150.00 | 05/02/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141722660 | CMS |
| Merck Sharp & Dohme LLC | $1,193.72 | 05/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141722656 | CMS |
| Merck Sharp & Dohme LLC | $121.33 | 05/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141722814 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $9.75 | 04/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086095475 | CMS |
| PFIZER INC. | $17,120.00 | 04/25/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131587170 | CMS |
| AstraZeneca Pharmaceuticals LP | $86.26 | 04/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104227261 | CMS |
| AstraZeneca Pharmaceuticals LP | $85.17 | 04/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105211056 | CMS |
| Janssen Scientific Affairs, LLC | $17.14 | 04/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078851148 | CMS |
| Janssen Biotech, Inc. | $4,050.00 | 04/05/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078680605 | CMS |
| PFIZER INC. | $145.63 | 04/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131663775 | CMS |
| Astellas Pharma Europe Ltd | $1,275.00 | 03/25/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121141001 | CMS |
| PFIZER INC. | $102.17 | 03/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131585249 | CMS |
| PFIZER INC. | $236.15 | 03/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131596333 | CMS |
| PFIZER INC. | $500.00 | 03/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131618533 | CMS |
| PFIZER INC. | $11,539.60 | 03/23/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131618537 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $4,800.00 | 4 |
| PY2025 | Principal investigator | $1,048,759.23 | 132 |
| PY2024 | Recipient | $940.00 | 1 |
| PY2024 | Principal investigator | $1,572,363.97 | 142 |
| PY2023 | Recipient | $7,660.00 | 11 |
| PY2023 | Principal investigator | $300,949.93 | 71 |
| PY2022 | Recipient | $6,400.00 | 2 |
| PY2022 | Principal investigator | $149,126.84 | 32 |
| PY2021 | Principal investigator | $116,554.59 | 17 |
| PY2020 | Principal investigator | $75,972.52 | 14 |
| PY2019 | Principal investigator | $58,130.56 | 11 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
136 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $205,985.55 | 12/31/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | MK-5684-003# A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer mCRPC Previously Treated With Next-generation Hormonal Agent NHA | No dispute reported | 06/30/2026 | 1232929873 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $41,259.56 | 12/31/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next generation Hor | No dispute reported | 06/30/2026 | 1232930215 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35,248.00 | 12/29/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175354153 |
| Principal investigator 1 | Janssen Research & Development, LLC | $38,466.00 | 12/29/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1175354531 |
| Principal investigator 1 | Exelixis Inc. | $4,853.70 | 12/26/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222377670 |
| Recipient | PFIZER INC. | $3,200.00 | 12/22/2025 | Covered Recipient Physician | TALAZOPARIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727015 |
| Principal investigator 1 | Janssen Research & Development, LLC | $56,571.00 | 12/15/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1b Platform Study to Evaluate JNJ-78278343-based Therapeutic Combinations for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175354217 |
| Principal investigator 1 | Exelixis Inc. | $4,243.00 | 12/10/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377678 |
| Principal investigator 1 | Exelixis Inc. | $31,700.40 | 12/01/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222377668 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,227.00 | 11/28/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1175354161 |
| Principal investigator 1 | Exelixis Inc. | $2,230.00 | 11/19/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377672 |
| Principal investigator 1 | Exelixis Inc. | $2,416.00 | 11/19/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377674 |
| Principal investigator 1 | Exelixis Inc. | $2,836.00 | 11/19/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377676 |
| Principal investigator 1 | Exelixis Inc. | $2,314.00 | 11/19/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377680 |
| Principal investigator 1 | Janssen Research & Development, LLC | $25,545.00 | 11/10/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1175354508 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,000.00 | 11/07/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913695 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $500.00 | 11/07/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913697 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $200.00 | 11/07/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913699 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,000.00 | 11/07/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913713 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,000.00 | 11/07/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913715 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $500.00 | 11/07/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913755 |
| Principal investigator 1 | Janssen Research & Development, LLC | $46,475.00 | 11/03/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175354333 |
| Recipient | PFIZER INC. | $330.00 | 10/20/2025 | Covered Recipient Physician | MEVROMETOSTAT CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228727577 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.70 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913667 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $322.28 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913669 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.70 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913671 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.70 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913673 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $275.52 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913675 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $188.02 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913677 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $304.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913679 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $304.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913681 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $304.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913683 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $304.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913685 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $188.02 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913687 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $430.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913689 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.70 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913691 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $304.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913693 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $299.32 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913701 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $275.52 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913703 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $304.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913705 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $304.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913707 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $299.32 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913709 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.70 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913711 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.70 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913717 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $13.89 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913719 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $275.52 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913721 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $13.89 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913723 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $304.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913725 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $430.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913727 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $430.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913729 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $13.89 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913731 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $188.02 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913733 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $13.89 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913735 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.70 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913737 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.70 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913739 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.70 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913741 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $283.78 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913743 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $13.89 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913745 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $283.78 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913747 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $13.89 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913749 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.70 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913751 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $275.52 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913753 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $322.28 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913757 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $322.28 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913759 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $322.28 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913761 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.70 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913763 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $304.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913765 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $13.89 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913767 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $304.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913769 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $304.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913771 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $13.89 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913773 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.70 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913775 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $13.89 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913777 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $188.02 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913779 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $13.89 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913781 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.70 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913783 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $299.32 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913785 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $13.89 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913787 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $273.70 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913789 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $304.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913791 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $13.89 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913793 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $430.92 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913795 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,783.00 | 10/09/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175354521 |
| Principal investigator 1 | Exelixis Inc. | $2,890.00 | 09/10/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377566 |
| Principal investigator 1 | Exelixis Inc. | $2,999.00 | 09/10/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377570 |
| Principal investigator 1 | Exelixis Inc. | $4,225.00 | 09/10/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377576 |
| Principal investigator 1 | Exelixis Inc. | $3,056.00 | 09/10/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377578 |
| Principal investigator 1 | Exelixis Inc. | $2,477.00 | 09/10/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377580 |
| Principal investigator 1 | Exelixis Inc. | $4,138.00 | 09/10/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377582 |
| Principal investigator 1 | Exelixis Inc. | $3,116.00 | 09/10/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377586 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,519.00 | 09/08/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175354415 |
| Principal investigator 1 | Exelixis Inc. | $2,853.90 | 09/01/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222377588 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,000.00 | 08/14/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913623 |
| Principal investigator 1 | Janssen Research & Development, LLC | $54,250.00 | 08/04/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer | No dispute reported | 06/30/2026 | 1175354324 |
| Principal investigator 1 | Exelixis Inc. | $2,314.00 | 08/01/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377568 |
| Principal investigator 1 | Exelixis Inc. | $2,836.00 | 08/01/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377572 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $124.98 | 07/28/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913625 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,690.00 | 07/21/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175354406 |
| Principal investigator 1 | Exelixis Inc. | $28,268.70 | 07/17/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222377554 |
| Principal investigator 1 | Exelixis Inc. | $5,082.00 | 07/10/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222377552 |
| Principal investigator 1 | Exelixis Inc. | $3,000.00 | 07/10/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222377556 |
| Principal investigator 1 | Exelixis Inc. | $10,260.80 | 07/10/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222377558 |
| Principal investigator 1 | Exelixis Inc. | $2,447.00 | 07/09/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377574 |
| Principal investigator 1 | Exelixis Inc. | $2,314.00 | 07/09/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377584 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,780.00 | 06/23/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175354239 |
| Principal investigator 1 | Exelixis Inc. | $2,314.00 | 06/11/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377534 |
| Principal investigator 1 | Exelixis Inc. | $4,841.00 | 06/11/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377536 |
| Principal investigator 1 | Exelixis Inc. | $49,958.60 | 06/11/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222377538 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,611.00 | 06/06/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175354288 |
| Recipient | PFIZER INC. | $940.00 | 05/31/2025 | Covered Recipient Physician | ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228769019 |
| Principal investigator 1 | Exelixis Inc. | $10,310.60 | 05/13/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222377488 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,323.00 | 05/08/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175354187 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $124.98 | 04/28/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913657 |
| Principal investigator 1 | Exelixis Inc. | $9,234.00 | 04/11/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222377490 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,855.00 | 03/31/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175354454 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $500.00 | 03/25/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913639 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $750.00 | 03/25/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913641 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $500.00 | 03/25/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913643 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,250.00 | 03/25/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913645 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $500.00 | 03/25/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913647 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $1,000.00 | 03/25/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913649 |
| Principal investigator 1 | Exelixis Inc. | $29,012.10 | 03/19/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222377482 |
| Principal investigator 1 | Janssen Research & Development, LLC | $14,690.00 | 03/07/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175354476 |
| Principal investigator 1 | Exelixis Inc. | $94,644.40 | 03/03/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222377484 |
| Principal investigator 1 | Exelixis Inc. | $119.00 | 02/21/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377472 |
| Principal investigator 1 | Exelixis Inc. | $560.00 | 02/21/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377474 |
| Principal investigator 1 | Exelixis Inc. | $1,050.00 | 02/21/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377478 |
| Principal investigator 1 | Exelixis Inc. | $3,515.00 | 02/10/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377466 |
| Principal investigator 1 | Exelixis Inc. | $3,132.00 | 02/10/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377468 |
| Principal investigator 1 | Exelixis Inc. | $2,999.00 | 02/10/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377476 |
| Principal investigator 1 | Janssen Research & Development, LLC | $41,246.00 | 02/03/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cancer | No dispute reported | 06/30/2026 | 1175354181 |
| Recipient | PFIZER INC. | $330.00 | 01/28/2025 | Covered Recipient Physician | ENFORTUMAB VEDOTIN CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770513 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $124.98 | 01/27/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913637 |
| Principal investigator 1 | Aveo Pharmaceuticals, Inc. | $124.98 | 01/27/2025 | Covered Recipient Teaching Hospital Uh Cleveland Medical Center | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor | No dispute reported | 06/30/2026 | 1199913659 |
| Principal investigator 1 | Exelixis Inc. | $37,837.00 | 01/17/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222377486 |
| Principal investigator 1 | Exelixis Inc. | $3,648.00 | 01/15/2025 | Covered Recipient Teaching Hospital Rainbow Babies & Childrens Hospita | A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | No dispute reported | 06/30/2026 | 1222377480 |